• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OPRELVEKIN Drug Record

  • Summary
  • Interactions
  • Claims
  • OPRELVEKIN chembl:CHEMBL1201573 ApprovedAntineoplastic

    Alternate Names:

    OPRELVEKIN
    NEUMEGA
    AGIF
    INTERLEUKIN-11 PRECURSOR
    ADIPOGENESIS INHIBITORY FACTOR
    IL-11
    chembl:CHEMBL1201573
    rxcui:139994
    chemidplus:145941-26-0
    drugbank:00038

    Drug Info:

    Drug Class thrombotic
    Year of Approval 1997
    FDA Approval approved
    Drug Class protein
    Drug Indications thrombopoietic
    (2 More Sources)

    Publications:

    Nandurkar et al., 1996, The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor., Oncogene
    Romas et al., 1996, The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures., J. Exp. Med.
    Nandurkar et al., 1997, Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis., Blood
    Li et al., 2001, Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period., Reproduction
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Nandurkar et al., 1998, The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor., Stem Cells
    Yanagisawa et al., 2000, Astrocyte differentiation of fetal neuroepithelial cells by interleukin-11 via activation of a common cytokine signal transducer, gp130, and a transcription factor, STAT3., J. Neurochem.
    Fuhrer et al., 1996, Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11., Exp. Hematol.
    Suga et al., 2001, Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells., J. Interferon Cytokine Res.
    Kirkiles-Smith et al., 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression., J. Immunol.
  • OPRELVEKIN   IL11RA

    Interaction Score: 103.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name oprelvekin, YM 294, recombinant human interl/
    Mechanism of Interaction Interleukin 11 receptor alpha agonist

    PMIDs:
    8637716 8676079 9310465 11570967 11752352 11012177


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • OPRELVEKIN   MYOD1

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11576464


    Sources:
    NCI

  • OPRELVEKIN   GFAP

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10737606


    Sources:
    NCI

  • OPRELVEKIN   BIRC5

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14734714


    Sources:
    NCI

  • OPRELVEKIN   PIK3CG

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8641341


    Sources:
    NCI

  • OPRELVEKIN   PIK3CA

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8641341


    Sources:
    NCI

  • TEND: OPRELVEKIN

    • Version: 01-August-2011

    Alternate Names:
    OPRELVEKIN Primary Drug Name

    Drug Info:
    Year of Approval 1997
    Drug Class thrombotic

    Publications:

  • TdgClinicalTrial: OPRELVEKIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications thrombopoietic
    Drug Class protein
    FDA Approval approved

    Publications:

  • NCI: IL-11

    • Version: 14-September-2017

    Alternate Names:
    C1303 NCI drug code

    Drug Info:

    Publications:
    Kirkiles-Smith et al., 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression., J. Immunol.
    Yanagisawa et al., 2000, Astrocyte differentiation of fetal neuroepithelial cells by interleukin-11 via activation of a common cytokine signal transducer, gp130, and a transcription factor, STAT3., J. Neurochem.
    Fuhrer et al., 1996, Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11., Exp. Hematol.

  • TTD: Oprelvekin

    • Version: 2020.06.01

    Alternate Names:
    D0T1IJ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201573

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201573

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21